Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk. He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer. From 2017 to 2019, Thomsen was the chairman of the board of directors at University of Copenhagen.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Mads Krogsgaard Thomsen (en)
|
rdfs:comment
| - Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk. He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer. From 2017 to 2019, Thomsen was the chairman of the board of directors at University of Copenhagen. (en)
|
foaf:name
| - Mads Krogsgaard Thomsen (en)
|
name
| - Mads Krogsgaard Thomsen (en)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
birth date
| |
citizenship
| |
education
| |
title
| - CEO of Novo Nordisk Foundation (en)
|
has abstract
| - Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman, CEO of the Novo Nordisk Foundation and former Executive Vice President of Research & Development, head of R&D and Chief Scientific Officer (CSO) at the pharmaceutical company Novo Nordisk. He was appointed senior vice president of Diabetes R&D in 1994 and in November 2000 he was appointed executive vice president and chief science officer. Mads Krogsgaard Thomsen was employed by Novo Nordisk in 1991 as head of Growth Hormone Research and became Executive Vice President for Diabetes R&D in 1994. In November 2000 he was appointed executive vice president and Chief Scientific Officer (CSO). From 1994 to 2021 he was responsible for the research and development of 20 medical products especially within diabetes treatment and the groundbreaking development of GLP-1 and tablet technology used as replacement for conventional injection-based technology in biological diabetes treatment. Mads Krogsgaard Thomsen left the position as Senior Vice President o R&D on February 28 in 2021 for the position as CEO of the Novo Nordisk Foundation where he replaced Birgitte Nauntofte. He took over the role as CEO on March 1, 2021. From 2017 to 2019, Thomsen was the chairman of the board of directors at University of Copenhagen. (en)
|
boards
| - Technical University of Denmark , University of Copenhagen (en)
|
employer
| - Novo Nordisk Foundation (en)
|
board
| |
person function
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
birth year
| |
title
| - CEO of Novo Nordisk Foundation (en)
|
employer
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is foaf:primaryTopic
of | |